Christopher Herring
Vice President of Biology & Safety
Chris serves as the Vice President of Biology and Safety at T-Therapeutics, bringing extensive experience in the cell and gene therapy space.
Prior to T-Therapeutics, Chris was Senior Director and then VP of Discovery Research at Adaptimmune, leading the early discovery pipeline from mass spectrometry, target and TCR discovery through to next-generation T cell engineering teams.
Before that he led groups and projects in GSK’s Cell and Gene Therapy Discovery Research Group working on CAR-T, TCR-T and AAV vectored antibody projects.
He has extensive experience from GSK and Domantis in developing half-life extended biologics, as well as bispecific and other novel antibody-based formats including immunocytokines.
Chris holds a PhD in Oncology from the Paterson Institute for Cancer Research (University of Manchester) and a BSc(Hons) from the University of Surrey.
